QuantSignals › Forecasts › NVO
KATY's daily model path, its record on NVO, and the options read. Prices as of the Nov 10, 2026 close · page updated Nov 10, 2026.
Last close
$40.70
Nov 10, 2026 · −1.64% on the day
KATY call
BUY
run Nov 6, 2026
Path end (20 sessions)
$44.43
+10.21% from $40.31
Path range
+1.2% to +10.2%
lowest and highest point of the path
Replay record on NVO
12/14 hits
85.7% · 2 misses
Options
CHEAP
IV 31% · 0.93× realized
KATY's latest public daily path for Novo Nordisk, from its run on Nov 6, 2026, points up, which KATY labels BUY. Starting from the $40.31 close, the path ends 20 sessions later near $44.43 (+10.21%), around Dec 4, and ranges between +1.16% and +10.21% along the way. That is a model path, not a price target.
Since that run, NVO has closed at $40.70 on Nov 10, 2026, +0.97% from the start, 2 of 20 sessions in. So far the move agrees with the path. The call is scored after session 20.
On NVO, KATY's replay record is 12 hits and 2 misses in 14 tested calls (85.7%), above its 50.1% rate across all tickers. Its most recent completed replay call expected +10.94% and NVO moved +4.32%: a hit on direction.
In options, the at-the-money 2026-12-18 contract trades at 31% implied volatility against about 34% realized, 0.93× realized, so options read cheap. That is a pricing read, not a signal.
Daily closes, with KATY's Nov 6, 2026 path drawn from its start close to its end point; the shaded wedge spans the path's lowest and highest points.
The KATY apps and extension show the newest NVO path as soon as it runs, with the full step-by-step line on the chart. They are free to install; live forecasts need KATY Premium or an FST membership.
Every public NVO path this page has captured, scored on the close 20 sessions after its start: a BUY is a hit if that close is higher, a SELL if it is lower.
| Run | Call | Start close | Path end | Outcome at 20 sessions |
|---|---|---|---|---|
| Nov 6, 2026 | BUY | $40.31 | $44.43 (+10.21%) | Open, 2/20 sessions · +0.97% so far |
12 hits, 2 misses and 1 neutral in 14 replayed NVO calls (85.7% on direction; 71.4% finished inside the 1.5% band; average path error 5.98%). Across all tickers KATY's replay hit rate is 50.1% over 1,023 calls (BUY > +1.5%, SELL < -1.5% on the 20-step path). Replays re-run the model on past data it did not see; they are not live trades.
KATY re-forecast the 20 sessions that just finished without seeing them. It expected +10.94%; the actual move was +4.32% (direction hit, average path error 3.6%).
| Step | Session | Model path | Actual close | Path vs actual |
|---|---|---|---|---|
| 1 | Oct 12, 2026 | $38.88 | $38.58 | +0.78% |
| 5 | Oct 16, 2026 | $39.75 | $38.83 | +2.37% |
| 10 | Oct 23, 2026 | $40.42 | $39.05 | +3.51% |
| 15 | Oct 30, 2026 | $41.60 | $40.00 | +4.00% |
| 20 | Nov 6, 2026 | $42.87 | $40.31 | +6.35% |
The at-the-money 2026-12-18 NVO option (38 days) is priced at 31.4% implied volatility, 0.93× the stock's realized volatility, which reads cheap. Cheap or rich is a pricing read, not a signal. See the full options-value screen.
KATY's latest public daily path for NVO (run Nov 6, 2026) is BUY: from $40.31 it ends near $44.43 (+10.21%) after 20 sessions. It is a model path, not a price target. The newest path is in the KATY apps (free to install; live forecasts need KATY Premium or an FST membership).
In replay, KATY called the direction of NVO right 12 times and wrong 2 times out of 14 tested calls (85.7%). Public calls on this page are scored after 20 sessions and listed above, misses included.
KATY is a time-series foundation model that reads the recent daily bars of NVO and draws the most likely path for the next 20 sessions. A path that ends more than 1.5% up is a BUY, more than 1.5% down a SELL, and anything in between is NEUTRAL. It is not investment advice.
KATY draws this forecast on your own charts: in TradingView with the Chrome extension, or on your phone. The extension and apps are free to install; live forecasts need KATY Premium or an FST membership.
Healthcare & biotech
Most viewed
Not investment advice. KATY's output is a model path, not a price target and not a recommendation to buy or sell. Model forecasts are often wrong; the hit and miss counts on this page are shown so you can judge that yourself. Trading involves risk of loss. Data from QS Research; prices are daily closes and may lag.